Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency

Spruce Biosciences Presents Phase 2 Data for Tildacerfont in Adults with Congenital Adrenal Hyperplasia at 23rd European Congress of Endocrinology

Retrieved on: 
Monday, May 24, 2021
Health, Other Health, Clinical trials, General Health, Pharmaceutical, Biotechnology, Medicine, Medical specialties, Organ systems, Congenital adrenal hyperplasia, Adrenal gland disorders, Hyperplasia, Adrenal gland, Rare diseases, Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency, Lipoid congenital adrenal hyperplasia, Tildacerfont, Spruce Biosciences, TILDACERFONT, SPRUCE BIOSCIENCES

Administration of tildacerfont to these patients did not lead to significant changes in these levels.

Key Points: 
  • Administration of tildacerfont to these patients did not lead to significant changes in these levels.
  • Tildacerfont has been evaluated in 171 patients across seven clinical trials in which it has been generally well tolerated.
  • Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need.
  • Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH).

Spruce Biosciences Presents Phase 1 and 2 Data for Tildacerfont in Adults with Congenital Adrenal Hyperplasia from Endocrine Society’s 2021 Annual Meeting

Retrieved on: 
Wednesday, March 17, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Organ systems, Medical specialties, Medicine, Adrenal gland disorders, Congenital adrenal hyperplasia, 17α-Hydroxyprogesterone, Hyperplasia, Adrenal gland, CAH, Congenital adrenal hyperplasia due to 21-hydroxylase deficiency, Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency, Tildacerfont, Spruce Biosciences

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need, presented data from its Phase 1 and 2 programs of tildacerfont in adults with classic congenital adrenal hyperplasia (CAH) from the Endocrine Societys 2021 Annual Meeting , taking place virtually March 20 23, 2021.

Key Points: 
  • Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need, presented data from its Phase 1 and 2 programs of tildacerfont in adults with classic congenital adrenal hyperplasia (CAH) from the Endocrine Societys 2021 Annual Meeting , taking place virtually March 20 23, 2021.
  • Participants in the study underwent concurrent salivary and serum concentration measurements of androstenedione (A4), 17-hydroxyprogesterone (17-OHP) and testosterone (T).
  • Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need.
  • Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH).

Congenital Adrenal Hyperplasia Epiomic Epidemiology Forecasts 2018-2028

Retrieved on: 
Monday, September 17, 2018
Adrenal gland disorders, Medicine, Endocrine system, Endocrinology, Congenital adrenal hyperplasia, Adrenal gland, Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency, Mineralocorticoid, Cytochrome P450 reductase, Glucocorticoid, Steroid, Lipoid congenital adrenal hyperplasia

The "Congenital Adrenal Hyperplasia Forecast In 31 Major Markets 2018-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Congenital Adrenal Hyperplasia Forecast In 31 Major Markets 2018-2028" report has been added to ResearchAndMarkets.com's offering.
  • Congenital adrenal hyperplasia (CAH) is a group of genetic disorders associated with deficiencies of several adrenal enzymes which lead to abnormal production of glucocorticoids, mineralocorticoids and sex steroids.
  • This, in turn, affects metabolism, sodium and water balance and the development of primary or secondary sex characteristics.
  • CAH can occur in classic (severe) or non-classic (mild) forms depending on the amount of residue enzyme activity.